Literature DB >> 21593650

Oral viscous budesonide therapy in children with epidermolysis bullosa and proximal esophageal strictures.

R Dohil1, S S Aceves, M A Dohil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21593650     DOI： 10.1097/MPG.0b013e31820a9310

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN： 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  6 in total

1.  Oral viscous budesonide as a first-line approach to esophageal stenosis in epidermolysis bullosa: an open-label trial in six children.

Authors:  Andrea Zanini; Sophie Guez; Simona Salera; Giorgio Farris; Anna Morandi; Valerio Gentilino; Ernesto Leva; Francesca Manzoni; Maria Angela Pavesi; Susanna Esposito; Francesco Macchini
Journal:  Paediatr Drugs       Date:  2014-10       Impact factor: 3.022

2.  From genetics to treatment of eosinophilic esophagitis.

Authors:  Antonella Cianferoni; Jonathan M Spergel
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-10

Review 3.  Eosinophilic Esophagitis and Gastroenteritis.

Authors:  Antonella Cianferoni; Jonathan M Spergel
Journal:  Curr Allergy Asthma Rep       Date:  2015-09       Impact factor: 4.806

4.  Pain care for patients with epidermolysis bullosa: best care practice guidelines.

Authors:  Kenneth R Goldschneider; Julie Good; Emily Harrop; Christina Liossi; Anne Lynch-Jordan; Anna E Martinez; Lynne G Maxwell; Danette Stanko-Lopp
Journal:  BMC Med       Date:  2014-10-09       Impact factor: 8.775

Review 5.  Emergency management in epidermolysis bullosa: consensus clinical recommendations from the European reference network for rare skin diseases.

Authors:  Jemima E Mellerio; Maya El Hachem; Nathalia Bellon; Giovanna Zambruno; Hana Buckova; Rudolf Autrata; Carmen Salavastru; Tamara Caldaro; Celine Greco; Cristina Has; Christine Bodemer
Journal:  Orphanet J Rare Dis       Date:  2020-06-06       Impact factor: 4.123

Review 6.  Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis bullosa.

Authors:  Verena Wally; Manuela Reisenberger; Sophie Kitzmüller; Martin Laimer
Journal:  Orphanet J Rare Dis       Date:  2020-10-19       Impact factor: 4.123
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.